Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medi

Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medi (BioFlorida)

UF startup and Sid Martin Biotech alum Ology Bioservices, Inc., a biologics contract development and manufacturing organization, and Rafa Laboratories, Ltd., a leading Israeli pharmaceutical company, announced that on July 9, 2018, they received full approval from the U.S. Food and Drug Administration (FDA) for the Atropine Injection, 2mg/0.7mL, Single-Dose Autoinjector. The Atropine Autoinjector initially received Emergency Use Authorization from the FDA in April 2017. Atropine is one of the most commonly used drugs for the treatment of chemical nerve agent poisoning. With the approved autoinjector, U.S. troops can rapidly inject atropine into the thigh muscle following nerve agent exposure.

Learn more about Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medi.

X